Dose Escalation Study of ARQ 736 in Adult Subjects With Advanced Solid Tumors Harboring BRAF and/or NRAS Mutations
Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
This is an open-label, Phase 1, dose escalation study of oral ARQ 736 administered to
subjects with advanced solid tumors harboring the mutation. The study is designed to explore
the safety, tolerability, pharmacokinetics and pharmacodynamics of ARQ 736 and to define a
recommended Phase 2 dose of ARQ 736.
Phase:
Phase 1
Details
Lead Sponsor:
ArQule ArQule, Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck & Co., Inc.)